Onesource Specialty Pharma Limited — Updates, 04-08-2025: Press Release

OneSource reports strong Q1 performance: Revenue at ₹327.3 Cr (+12% YoY), EBITDA ₹88.5 Cr (+37% YoY), and adjusted PAT ₹37.1 Cr (swing to profit). Operational momentum continues with 6 new contracts and DDC capacity expansion. The flagship facility cleared USFDA and ANVISA inspections, bolstering commercialization readiness. The Board is evaluating a strategic acquisition of two USFDA-approved Steriscience manufacturing sites in Poland and India, aiming to expand specialty injectables and DDC capabilities. The company reaffirms its FY28 targets of >30% revenue CAGR and ~40% EBITDA margins.